Volume : 09, Issue : 03, March – 2022

Title:

26.CURRENT INNOVATION IN ANTI-HIV DRUG DISCOVERY AND PRODUCT DEVELOPMENT: A REVIEW
‬

Authors :

Ayush Soni*, Avdesh Kushwaha, Bhumika Kshetrapal, Rupesh Jain*

Abstract :

Rapid development of multidrug-resistant HIV strains, poor bioavailability, and cumulative toxicities have hampered the early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV infection, necessitating the development of alternative antiretroviral drug discovery strategies and additional therapeutic agents with novel action modes or targets. From this standpoint, we first evaluate current antiretroviral medication discovery and optimization methodologies, using cases from the recent literature as examples. The advent of the substrate envelope concept as a new technique for overcoming HIV drug resistance is highlighted, as is the discovery of phosphate ester-based prodrugs as a means of improving HIV inhibitors’ water solubility. Present review focus on HIV Life Cycle, Anti-HIV Drug Discovery, Classes of currently approved drugs, Summary of the possible HIV targets and interventions, Anti-HIV Drugs Development, Perspectives that could inspire future anti-HIV drug discovery.

Cite This Article:

Please cite this article in press Rupesh Jain et al, Current Innovation In Anti-Hiv Drug Discovery And Product Development: A Review ., Indo Am. J. P. Sci, 2022; 09(3),.

Number of Downloads : 10

References:

1. Menéndez-Arias, L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res. 2013, 98, 93−120.
2. Ghosh, R.K.; Ghosh, S.M.; Chawla, S. Recent advances in antiretroviral drugs. Expert Opin. Pharmacother. 2011, 12, 31−46.
3. Zhang, J.; Crumpacker, C. Eradication of HIV and cure of AIDS, now and how? Front Immunol. 2013, 4, 337.
4. De Clercq, E. Antiretroviral drugs. Curr. Opin. Pharmacol. 2010, 10, 507−515.
5. Edward C, Klatt MD. Pathology of HIV/AIDS; 2016.
6. Carolina HA, Lenis MF, Valeria O. TwentySix Years of HIV science: An overview of anti-HIV drugs metabolism. Brazilian J. of Pharmaceut. Sci. 2011;47:2.
7. Ashraf B, Chi-Huey W. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 2003;1:5–14.
8. Marr Lisa, Batimore MD. Sexually transmitted diseases: A physician tells you what you need to know, Johns Hopkins University Press; 1998.
9. Ching WS, Yee-Joo T. Review viral membrane channels: Role and function in the virus life cycle. Viruses. 2015;7:32613284.
10. HIV life cycle. A Project of the International Association of Providers of AIDS Care and the New Mexico AIDS Education and Training Center; 2014. Available:www.aidsinfonet.org
11. Esposito F, Zinzula L, Tramontano E. Antiviral drug discovery: HIV-1 RNase H, the next hit target, Communicating Current Research and Educational Topics and Trends in Applied Microbiology; 2007. Behja and Jemal; IRJPAC, 20(3): 1-16, 2019; Article no.IRJPAC.52536 15
12. Jones PS. Review strategies for antiviral drug discovery. Antiviral Chemistry & Chemotherapy. 1998;9:123-333.
13. Paul AJ, Janssen PJ, Lewi EA, Frits D, Marc J, Jan H, Luc K. In search of a novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile (R278474, Rilpivirine). J. of Med. Chem. 2004;8:1.
14. Christopher J, Michejda NP, Marshall M, San Diego CA, Thomas R. Substituted benzimidazoles and methods of use, the Inhibition of HIV reverse Transcription and for the Treatment of HIV Infection, U.S. Patent. 2002;Sheet 2 of 20.
15. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of antiAIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors, j. pbiomolbio. 2004;07:001.
16. Clare S. Drug design: HIV; 2009. Avaliable:www.chemistryworld.org
17. De Clercq E. Antiretroviral drugs.Curr Opin Pharmacol. 2010;10:507-15.
18. Basavapathruni A, Anderson KS. Reverse transcription of the HIV-1 pandemic The FASEB Journal. 2007;21:3795–3808.
19. Stephen R, James J, Marilyn B. New drugs for treatment for AIDS and cost implication. The Health Education Monograph Series. 1997;15:2.
20. Ju H,Zhang J, Huang B, et al. Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. J Med Chem. 2017;60(9):3533-3551.
21. DeSimone RW, Currie KS, Mitchell SA, et al. Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen. 2004;7(5):473-94.
22. Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol. 2010;14(3):347-61.
23. Zhao H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov Today. 2007;12(3-4):149-55.
24. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311-35.
25. Li G, Lou HX. Strategies to diversify natural products for drug discovery. Med Res Rev. 2017; Oct 24. [Epub ahead of print].
26. Huang B, Kang D, Yang J, et al. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opin Ther Pat. 2016;26(2):281-9.
27. Pertusati F, Serpi M, McGuigan C. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antivir Chem Chemother .2012 :22(5):181-203
28. Stumpfe D, Hu Y, Dimova D, et al. Recent progress in understanding activity cliffs and their utility in medicinal chemistry. J Med Chem. 2014:57(1):18-28